Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SY002 for treatment of fever in adults with respiratory infection
CTR20261633Phase 2Active
- Sponsor
- Jiacheng Biomedical
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ropivacaine in fever (2 arms), sponsored by Jiacheng Biomedical. Primary endpoint: Difference in temperature-time curve within 4 hours after first dose. Started Apr 2026; status: active.
02
Drugs
ropivacaine
03
Conditions
fever
Beyond the preview
Go deeper on CTR20261633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261633.